αααααβααΎαPHS β’ FRA
add
Photocure ASA
5.05β¬
25 αα»αααα, 11:46:16 PM ααααβααα +1 · EUR · FRA · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
αα·αααΈαα»α
5.10β¬
α
αααααααααααα
5.05β¬ - 5.05β¬
α
ααααααα½αααααΆαα
α»αααααα
3.97β¬ - 6.65β¬
ααα ααα½αααΌαααααα
25.00
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααααααΆαααΈααααΆα
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (NOK) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 136.67Β ααΆα | -3.54% |
α
αααΆαααααα·ααααα·ααΆα | 131.26Β ααΆα | -1.32% |
α
αααΌααα»ααα | -7.95Β ααΆα | -84.25% |
ααααΆααα
αααααα»ααα | -5.82 | -90.82% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | -0.30 | -42.86% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 1.92Β ααΆα | -66.61% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 15.56% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (NOK) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 238.89Β ααΆα | -17.29% |
ααααααααα»α | 707.06Β ααΆα | -4.33% |
ααΆαααα½ααα»αααααΌαααα»α | 222.83Β ααΆα | -6.13% |
ααΌαβααααα»α | 484.23Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 26.61Β ααΆα | β |
ααααααααααΉαααααα
| 0.28 | β |
ααα
ααααααΎαααααα | -1.96% | β |
ααα
ααααααΎααΎααα»α | -2.78% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (NOK) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | -7.95Β ααΆα | -84.25% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | -473.00Β ααΆαα | -103.07% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -1.29Β ααΆα | 21.11% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -7.11Β ααΆα | 35.21% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | -8.88Β ααΆα | -416.92% |
ααα αΌαααΆα
αααααΆααααααα | -2.15Β ααΆα | 54.62% |
α’αααΈ
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. Wikipedia
ααΆααααααΎαα‘αΎα
1993
αααααβαααααΆα
αα»ααααα·α
102